(Q38543238)

4 September 2017

1 reference

title

Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder (English)

1 reference

4 September 2017

G I Papakostas

1

1 reference

4 September 2017

D F Ionescu

series ordinal

2

1 reference

4 September 2017

language of work or name

English

0 references

publication date

7 July 2015

1 reference

4 September 2017

1 reference

4 September 2017

volume

20

1 reference

4 September 2017

issue

10

1 reference

4 September 2017

page(s)

1142-1150

1 reference

Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Diagnosis and definition of treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Antidepressant effects of ketamine in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

A single infusion of ketamine improves depression scores in patients with anxious bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

A randomized controlled trial of intranasal ketamine in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

A double-blind, placebo-controlled study of memantine in the treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

An open-label trial of riluzole in patients with treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Riluzole likely lacks antidepressant efficacy in ketamine non-responders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Mood disorders: regulation by metabotropic glutamate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Scopolamine as an antidepressant: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Antidepressant treatment history as a predictor of response to scopolamine: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Scopolamine Produces Larger Antidepressant and Antianxiety Effects in Women Than in Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Nicotinic acetylcholine receptors as targets for antidepressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

(S)-(+)-mecamylamine (TC-5214): a neuronal nicotinic receptor modulator enters phase III trials as an adjunct treatment for Major Depressive Disorder (MDD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

α4β2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

A randomized, double-blind, placebo-controlled phase 2 study of the augmentation of a nicotinic acetylcholine receptor partial agonist in depression: is there a relationship to leptin levels?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Opiates as antidepressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Evaluation of opioid modulation in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

An overview of vortioxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Vortioxetine for the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or ag

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Inflamed moods: a review of the interactions between inflammation and mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Treating the depressions with superficial brain stimulation methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Neurobiology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Non-invasive magnetic stimulation of human motor cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Three-dimensional distribution of the electric field induced in the brain by transcranial magnetic stimulation using figure-8 and deep H-coils

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Transcranial magnetic stimulation in the management of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

The efficacy and safety of low frequency repetitive transcranial magnetic stimulation for treatment-resistant depression: the results from a large multicenter French RCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Deep transcranial magnetic stimulation as a treatment for psychiatric disorders: a comprehensive review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

H-coil repetitive transcranial magnetic stimulation for treatment resistant major depressive disorder: An 18-week continuation safety and feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

The nature of placebo response in clinical studies of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Empirical testing of two models for staging antidepressant treatment resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Updates and trends in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Rapid mood-elevating effects of low field magnetic stimulation in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.92

Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness

21 January 2018

1 reference

12 December 2020

Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.

1 reference

12 December 2020

Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression

1 reference

12 December 2020

When at first you don't succeed: sequential strategies for antidepressant nonresponders

1 reference

12 December 2020

Ketamine safety and tolerability in clinical trials for treatment-resistant depression

1 reference

12 December 2020

Comparing the effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in the treatment of depression: a systematic review and meta-analysis

1 reference

12 December 2020

Pharmacologic treatment of dimensional anxious depression: a review

1 reference

12 December 2020

Identifiers

DOI

10.1038/MP.2015.92

1 reference

Dimensions Publication ID

4 September 2017

1002517231

0 references

1 reference